Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow stromal cells
- Development stage
- Phase 2
- Lead developer
- Fundación Investigación Biomédica Hospital Universitario Puerta de Hierro-Majadahonda
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal
01
Overview
Autologous bone marrow stromal cells, specifically the formulation designated as medicament NC1, is an advanced cell therapy product developed by the Fundación Investigación Biomédica Hospital Universitario Puerta de Hierro-Majadahonda. The therapy consists of mesenchymal stromal cells (MSCs) that are harvested from the patient's own bone marrow, expanded in vitro, and suspended in autologous plasma. It is administered via intrathecal injection into the subarachnoid space. The treatment is primarily investigated for chronic incomplete spinal cord injury (ASIA/Frankel grades B–D), where the MSCs are thought to exert therapeutic effects through the secretion of neurotrophic and neuroprotective factors. These paracrine effects aim to modulate the inflammatory microenvironment and promote neural repair and functional recovery.
- Other names
- medicament NC1autologous bone marrow-derived mesenchymal stromal cellsautologous bone marrow-derived MSCs
02
Targets
COL4 (Collagen IV)
Beyond the preview
Go deeper on autologous bone marrow stromal cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow stromal cells.